Galmed Reports Interim Results from the Open-Label Part of the ARMOR Study with Aramchol Showing Robust Fibrosis Improvement across Multimodality Histological Assessment

Galmed Pharmaceuticals Ltd. announced interim results from the Open-Label Part of the ARMOR study showing fibrosis improvement with Aramchol using multimodality histological assessment.